InMed Pharmaceuticals (INM) EBIT (2021 - 2026)

InMed Pharmaceuticals has reported EBIT for 6 years, with the latest figure at -$2.8 million in Q1 2026.

• On a quarterly basis, EBIT fell 46.32% year-over-year to -$2.8 million in Q1 2026; TTM through Mar 2026 was -$9.2 million, a 15.78% decrease from a year earlier, with the FY2025 full-year figure at -$7.9 million, up 3.05% from the prior year.
• EBIT was -$2.8 million for Q1 2026 at InMed Pharmaceuticals, down from -$2.1 million in the prior quarter.
• The five-year high for EBIT was -$485150.0 in Q2 2023, with the low at -$6.5 million in Q2 2022.
• Average EBIT over 5 years is -$2.5 million, with a median of -$2.2 million recorded in 2023.
• The sharpest annual moves came in 2023 and 2024: EBIT jumped 92.56% in 2023, then sank 319.3% in 2024.
• Over 5 years, EBIT stood at -$2.2 million in 2022, then gained by 25.7% to -$1.6 million in 2023, then slumped by 37.03% to -$2.3 million in 2024, then rose by 6.72% to -$2.1 million in 2025, then slumped by 32.78% to -$2.8 million in 2026.
• The last three EBIT figures came in at -$2.8 million (Q1 2026), -$2.1 million (Q4 2025), and -$1.8 million (Q3 2025), per Business Quant data.